exercise ; cardiovascular system



EH




HF
follow-up
reporting ; cell ; Anand
doxorubicin
doctors ; blood transfusions
FM

devices ; heart failure
dXA
disease

hz ; pna
exercise ; cardiovascular
Renal artery stenosis

surgery ; heart transplant recipients

molecular mechanism
tertiary referral centre

HF



mortality
breathing ; heart beat
environment

heart failure ; Latin America


Heart rate

doctors
Nutrition ; heart failure
northwest united states


surgery
heart failure


Heart failure

clin

trans

CHF
autonomic balance
competitive
intermediate frailty
HFpEF
ST2

dodson

LV fibrosis ; mice

Jehovah ; witness ; anemia
medical conditions
heart failure
cardiac transplantation
co
frailty ;HF
cognitive function
Heart failure ; cognitive impairment
HF ; HF
follow-up duration
department of cardiology ; hospital
exercise
Heart rate ; cardiac patients
remote ischemic conditioning ; heart failure
air pollution ; heart failure

Sham-operated animals


policy
compliance ; treatment

taxonomy
CHF
Heart failure ; uk

cardiovascular disease
HF ; MI

Heart failure
markers of hemostasis

Caspase-3 ; gene expression ; heart failure
diuretic ; heart failure
right heart failure ; pulmonary hypertension
Heart failure ; bisphosphonates
functional capacity
etiology ; MR ; MS
hypertension
HF
Heart rate ; arterial pressure

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure

internal reliability ; cronbach
HFpEF
ejection fraction ; bNP
Pigs ; antiarrhythmic medication
beta blockade
CHF ; intubated
circulatory arrest
functional capacity

collected ; systolic dysfunction


exercise ; heart failure
implanted monitoring devices

conditions
HR ; Ea ; afterload burden
strokes

RAS ; atherosclerosis
frailty ; heart failure
microRNAs ; heart failure ; disease management
Hazard ratios ; cox regression
pss ; exercise training
heart failure ; ejection fraction
Cardiology ; bromodomain inhibition ; heart failure

vasopressin ; congestive heart failure
Mitral stenosis ; medical ; heart failure
heart failure ; cardiovascular death
Trastuzumab-related cardiotoxicity ; breast cancer
Devices ; heart failure ;HF ; therapy
sts ; hm
pde2 ;HF
hospital
Heart failure ; public health
albumin level
VET ; aortic pressure curve
physician continuity ; discharge
Medication regimen ; sst2

Cardiac symptoms
spironolactone ; systolic heart failure
eRK ; molecular scaffolds ; heart pathology
functional MS ; MR
chronic heart failure ; bisoprolol
Heart failure ;HF ; society
cox

Tolvaptan ; vasopressin ; receptor antagonist
arrhythmia-related costs ; expenditures
metric ; readmission metrics
readmission metric

follow-up


black patients
mechanism ; et ; CHF
stable ;HF
follow-up

propensity
baseline ; HRQol
ejection fraction outcomes trial
biomarkers ; chronic heart failure
hf ; cardiovascular hospitalization
cardiac ; inflammatory biomarkers
mortality
heart failure
Pharmacological ; acute heart failure
baseline ; heart failure
off-pump ; sparing ; HeartMate II exchange
dialysis ; device implantation
Coronary angiography
Hemodynamic phenotype ; Fontan
ms ; surgery ; echocardiography
exercise
factors
heart failure ; cox
Nordic walking ; heart failure
Psychometric testing ; self-care of Heart Failure index
multiorgan failure ; sepsis
acute kidney injury
VO2max
cox proportional hazards
Seattle Heart Failure model
healthcare
heart failure



cardiac
benefits

HR ;HF

drug ; japan
biomarkers
tug test
ESRD
Heart failure ; left ventricular ejection fraction
readmissions
systolic HF

lVAD implantation
postsystolic function
medication ; hemodynamics

aac ; cardiac hypertrophy
AHA ; ESC
physical ; heart failure
keletal muscle abnormalities ; exercise capacity ; Fontan circulation
Readmission ; hospital ; heart failure
lead ; hypertension ; kidney failure
chronic kidney disease ;CKd
income ; expenditure ; health
change
HR variability ; cardiac death
circulation
toxicity ; systemic blood pressure



north America
cPGs
MS ; surgery

acute heart failure
heart failure
stand-alone diagnostic devices ; hf
heart failure
HF
endothelial function ; flow-mediated dilatation
Race ; spironolactone ; heart failure
heart failure ; cardiac rehabilitation
Rhythm- and rate-control
exercise
benefits ; anemia ; heart disease
hf
Myocardial infarction ; Wistar rats
treatment algorithms ; post-LVAD AI
AI
sinus rhythm ; af
public reporting

telehealth ; medicare
diagnostic ; filling pressures

hawt ; chromatin hyperacetylation

acute heart failure

ms ; surgery
gls ; cv ; AF
deficit index

follow-up
mortality

QRs

CHF ; unilateral renal DNx ; cardiac autonomic balance
mitral regurgitation ; hf ; surgery
renin-angiotensin-aldosterone system inhibitors ; heart failure
anaerobic threshold ; heart failure
MS
af ; echocardiographic examination

economic savings ; accounting ; cost
PVf ; recovery ; pb

heart lesions
ms ;HF ; ms
ICU
bioinformatic ; heart failure
cardiovascular events
diuretic ;HF
CAD ; systolic HF
resistin ; metabolism ; heart disease
sst2 ; benefit ; BB therapy
Heart block ; induced ; pulmonary artery snared ; BiVP
compliance
ct ; dialysis-dependent patients
beta-blockers
CHF
RM
hf
Cardiac function ; pressure-volume conductance catheter system
evidence ; dilated cardiomyopathy
unfolded protein response ; cardiac sodium current ; systolic human heart failure
hypoalbuminemia ; heart failure
LV dysfunction ; MR ; ms
cd ; hf
angiotensin receptor ; neprilysin inhibitor ; heart failure
western blot ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
cardiomyopathy ; mortality
hff
heart transplant ; ecCT
proteome ; HDl particles ; shotgun
HF
southeastern Minnesota ; hh
branch block ; electrical activation sequence
hHF ; dp-4 inhibitors ; drugs
proteins ;TAC
Cardiac cachexia ;cc ; body composition
cardiac remodelling
dialysis
neurological
coronary disease ; heart failure
fm ; FM ; body weight ;cc
heart failure
exercise training ;ET ; endothelial function
ms ; mva
exercise ; exercise time
heart rate variation
cRF
DASh ; diet scores
rehospitalization
nitroxyl ; hno ; heart failure
Cardiac-resynchronization therapy ; heart failure
odds ratios ; accounting
change ; lVET ; follow-up measurement
blacks ; VO2 ; baseline
physician continuity ; urgent readmission ; discharge ; heart failure
hff ; hfpEF
hospital-to-Home ; hospital readmission reduction ; congestive heart failure
heart failure clinic
diabetes ; eEO-cFUs

transplants
aerobic exercise

trastuzumab-related CHF

Peak VO2
pharmaceutically
financials
Coronary artery disease ;CAD ; systolic heart failure ;HF
hypoalbuminemia ; lVAD ; surgery
psoriasis ; atherosclerosis ; cardiovascular events ; Rotterdam
mortality ;HF ; hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF antagonist
holosystolic murmur ; heart sound
cv ; death ; non-fatal stroke ; heart failure
hf ; haemodynamic ; neuronal stressors
deficit index ; mortality
right ventricular function ; body composition ; advanced heart failure
Fat ; cachexia ; right ventricle ; heart failure
atrial fibrillation ; af ; heart failure
ect ; advanced heart failure therapy
heart transplantation ; left ventricular assist device
exercise intolerance ; chronic heart failure
avd ; VVD ; free wall
connected ; heart failure
baseline ; eCGs ; electrocardiographers
left ventricular assist device ; right ventricular support
incidence ; ESRD ; outpatients ; hh
Wilcoxon ; matched-pairs signed-rank tests
subclinical atherosclerosis
Renal artery stenosis ;RAS ; peripheral arterial disease
baseline ; ect ; cardiac transplant recipients
eplerenone
recovery
extubated ; blood loss ; transfusion
technique ; exchange malfunctioning HeartMate II lVADs
Heart failure ;HF ; cardiovascular hospitalization
VEGF inhibition ; cardiac function
Î²-blocker ;BB ; sst2
miRNAs ; cardiac pathogenesis
cPET ; exercise rehabilitation ; CHF
heart failure ; ejection fraction
heart failure
Pediatric heart failure ;HF
expression ; regulatory subunit ;RI ;HF
follow-up medication
bromodomain proteins
mortality
heart failure ; readmission
bt ; dt ; implantation

hypotension
biomarkers ; treatment ; hf
hf
ST2 ; plasma samples
condition ; economic
medications ; heart failure
mortality rate
coronary heart disease ; stroke ; heart failure
mlf
septal defects ; surgical intervention
mortality ; iCD-HF
renal denervation ; autonomic balance ; rabbits ; chronic heart failure

trastuzumab
germline DNA
Heart failure disease management ; medical
Renal DNx ; circulating plasma ; CHF-inv rabbits
follow up ; hf
blood work ; medication
np assessment ; ED
Cardiac hypertrophy ; energy metabolism
lVAD implantation
HDL-bound malondialdehyde
renal dysfunction ; post-transplant
CAD ; CAD


hospital discharge

benefits ; anemia ; heart disease
right atrial myxoma ; pulmonary embolism ; right heart failure
nafat ; mir-25 ; transcription factor ; hand2 ; heart failure
resistin ; ejection fraction
Orthotopic heart transplantation ; owt ; heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
readmissions ; follow-up visits ; heart failure ; readmission quality improvement
lVAS ; bridge to transplantation
Cardiac overexpression ; Mammalian enabled ; mena ; heart failure
cps ; functional capacity ; peak VO2
pump failure ; driveline injury ; pump replacement
apoptosis ; canine model ; chronic heart failure ; tachycardia
Nicorandil ; doxorubicin
eh ; hfpEF
east ; rhythm control therapy ; cardiovascular complications ; AF
radiological ; hf
diuretics ; heart failure ;HF
evidence-based therapies ; fes
heart failure
Framingham Heart study ; hf ; EF
HF
acr ; CMS
band of activated Caspase ; paced myocardium
heart failure ; health ; body composition
hf ; saxagliptin ; sitagliptin
Heart t2 ; heart failure ; arrhythmias
ischemic ; abdominal problems ; MT
ed ; intubations ; congestive heart failure
medLine ;EMBAse ; cinahl
evidence ; aCP
exercise ; coronary artery disease ;CAD

change
ed ; CHF
benefit
Medicare ; post-acute care transfer policy
Diet score ; vegetables ; nuts

degs ; osprey

world health organization ; hf ; la
deficit index
implantation ; ct
evidence ; benefit
iron
remote monitoring ; hospital discharge ; heart failure
LV ; filling pressure ; stable systolic HF
Soluble ST2 ; ambulatory patients ; heart failure
baseline ; echocardiograms ; reverse remodeling
Titin hypophosphorylation ; myocardial DD
right ventricular contractile reserve ; pulmonary hypertension
bottleneck stent model ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD ; QT intervals ;SDQT
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
benefit ;RAS- ; Î²-blocker uptitration ;HFpEF
compliance ; exercise
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
noc ; admission ; discharge
HRQol ; exercise training ; baseline hgb
inpatient records ;HF
skeletal muscle mass ; VO2
cardiac catheterization ; extubated
psychosocial factors ; exercise training ; heart failure ;HF
medical ; heart failure ; children ; Canadian cardiovascular society
active
report model ; aRIC HF
atrial fibrillation ; pacemaker
mortality predictors ; iCD-HF
cardiovascular
catheter ablation ; sinus rhythm
body mass index ; cRF ; treadmill exercise testing
myocardial tissue ; pka
paediatric cardiac transplants
ventricular-arterial coupling ; SV
diastolic failure ; cardiomyopathic restriction ; flow
autonomic nervous system activity ; QTV
pneumonia ; conditions
technique ; myocardial fibrosis


exercise ; diet adherence
white
thics Rounds

biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
Heart Failure ; Pathophysiology ; medical
anemia ; heart disease ; american college of Physicians
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
renal disease ; outpatients ; systolic heart failure
rvpo ; BiVP ; RS synchrony
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
resistin ; anthracycline-induced cardiotoxicity
acute autonomic nervous system modulation ; qTV ;HF
Heart rate ; aortic blood flow ; doxorubicin

Myocardial pde2 ; activity ; hf
BAT ; sympathetic outflow ; parasympathetic activity
echocardiographic predictors ; reverse remodeling ; cardiac resynchronization therapy
cardiovascular death ; hf ; exercise training ; btes
exercise training ; chronic heart failure ; lipoprotein
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ; ghf
parasympathetic neurotransmission ; acetylcholinesterase inhibition
LVEF ; long-term mortality
DASh ; mortality ; heart failure ; women ; health Initiative
Jehovah ; Witness ; sickle cell disease ; anemia
miRNAs ; heart failure
dobutamine ; furosemide dose ; oxygen flow
health Buddy program ; ed
ca2 ; currents ; rad ; congestive heart failure
cps ; diabetes
anthracycline-treated breast cancer ; cardiotoxicity
pulmonary artery ; right pulmonary artery
mri scanner ; baseline ; heart failure

congestive heart failure ; chf
muscle-wasting syndrome ; acquired heart failure ; Fontan
health outcomes
ed ; CHF ; intubation rates
bisoprolol ; mortality
health Buddy program ; telehealth system ; care management
Medicare
conditions ; hospital discharge
heart failure
pss ; btes ; exercise
defense mechanism ; cardiac stress ; Î²-AR drive
mouse heart
co correlated ; septal wall ; avd ; free wall ; vd
LV ; strain rate ; echocardiography ; baseline
transplantation ; circulatory assist device
biventricular pacing ; left heart twist ; strain ; porcine model ; right heart failure
etiologic ; acute RV failure ; left ventricular dysfunction
cps ; functional capacity ; heart failure ;HF
protein kinase ; guanylate cyclase ; contractile response
circulating progenitor cells ; heart failure
Stress doppler echocardiography ; pulmonary hypertension
systolic ; diastolic mitral leaflet ; organic lesion
hf
ctnt ; NT-probNP ; hh
t test ; confidence intervals ; cis
radiological ;HF
inhospital mortality ; bNP ; mortality
aCS ; operation
right ventricle ;rv ; cardiac function ; medical
costs ; heart failure ;HF
RV dysfunction ; weight loss ; fat ;lean body mass ratio
HR reduction ; beta blockers ; exercise capacity ; hFrf
cardiopulmonary exercise ; heart failure
Canada
activity ; i-miBG ; myocardial washout
myocardial diastolic dysfunction ;dd
death ; heart failure
baseline ; ST2 ; interquartile range
black race ; mortality
Nursing-sensitive outcome change scores ; heart failure
diagnostic ; fluid overload
resistin ; chemotherapy-induced heart failure ; breast cancer
exercise
pressure ulcers ; surgical
hf ; valve plasty ; ms ; mva
pdp ; refractory ; end-stage congestive heart failure ;CHf
insurance status ; comorbidities
beta blockers ; mortality ; heart failure
transcatheter ; surgery
stopped ; safety monitoring board
complication
chelation regimens ; heart iron
MT ; consultation ; abdominal
Time up & go test ; chronic organ failure
NYha
follow-up visits
mortality
ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
aortic valve insufficiency ; left ventricular assist device implantation
ejection fraction ; cardiac resynchronization therapy ; heart failure
functional capacity ; walk test ; mwt
hff ; dietary sodium restriction ; ventricular ; vascular stiffness
magnetically Levitated left ventricular Assist system ; treatating Advanced HF
CHF ; atrial explants ; sham explants
chronic heart failure ; ghf ; sympathetic tone ; autonomic imbalance
Heart failure ; society ; cardiovascular diseases
extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
echocardiographic ; invasive hemodynamic
cardiac catheterization ; thrombotic obstruction ; right coronary artery
california ; statewide health planning ; Patient discharge data
Font failure ; systolic ventricular function ; liver disease
hf
apoptosis ; pacing-induced dilated cardiomyopathy
electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac comorbidities

economic ; af ; heart failure ; QuÃ©bec ; Canada
cardiac mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
bundle-branch block ;LBb ;LBb
protein ; western blot ; DNA fragmentation ; tunel method ; autopsy samples
herbal medicine ; dilated cardiomyopathy ; heart failure
implantable cardioverter-defibrillator deactivation
EH ; cardiac filling pressures
right atrium mass ; prolapse ; tricuspid valve ; stenotic
cutoff level ; NT-probNP
heart failure ; protein kinase ; expression
HF
Seattle Heart failure model scores
dopamine ; nesiritide strategy
nitrite
neurological ; cardiovascular ; event-free rate
cox regression ; cardiovascular events ; psoriasis
class iccp ; hh
flow-mediated dilatation improvement ; et
aHF
systolic function
BETs ; mouse ;TAC model ; hh
health ; benefits
cardiac nurses
consultations
transfusion thresholds ; mortality
Czech republic
MAD-ct study

UM ; va-RT
heart failure
western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; hh
preoperative serum albumin ; left ventricular assist device implantation
New York Heart association ; walk test
MS ; ring annuloplasty ; ischemic MR ; LV
Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
pathophysiology ; hf ; medical
ed physicians ; New Jersey ; New York
psoriasis ; smoked ; diastolic blood pressure ; body mass index
exercise intolerance ; heart failure ; exercise
echocardiography ; baseline ; shunt implantation
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
cox models ; ST2
TM ; sts
HRQol
NT-probNP ; circulation ; hh
energy metabolism ; heart failure ; hypertrophied heart
MS ; dynamic ; LV ; MS
PAD ; ankle-brachial index
HR reduction ; ivabradine ;TAC ; ea
baseline ; mechanical cardiac support ; renal function
ecmo ; VAD ; ecmo+VAD
mortality ; morbidity ; cancers ; budget
anticoagulation ; heart disease ; rate control
inotropic effect ; beta blockers ; heart failure
interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
heart failure ; systolic heart failure
baseline ; rhythm-control ; rate-control
hemoglobin levels ; health
functional MS ; medical ; treatment ; surgical
hf ; health service provision ; hf ; LA
Heart failure ;HF ; chronic disease
heart failure ;HF
CF lVAD ; AI ; heart failure
Treatment of anemia ; heart disease
left ventricular dilatation
ventricular assist devices ; device therapies
implanted
renal dysfunction ; mechanical cardiac
HF
computing readmissions ; hospital ; pay-for-performance
exploratory factor ; cfa
pb ; hf ; primary oscillations ; pattern generator

serum factors ; coagulability
iCD

bNP ; NT-probNP ; biomarkers ; heart failure
Cardiorespiratory ; body mass index ; heart failure mortality ; Cooper center longitudinal study
pro-adrenomedullin ;MR-proadm ; fm

Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
implantable cardiac defibrillator
ATP ; ROS ; mitochondrial respiration ; contractile function
physical activity ; cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
systolic HF ; etiology ; coronary angiography
rial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
circulating fragments ; natriuretic peptides ; plasma ; heart failure
heart failure ;HF ; left ventricular ejection fraction ; hpEF
heart failure ; implantation ; long-term ventricular assist device
hf ; cardiac murmurs ; blood pressure ; hg
receptors ; adenylyl cyclase ; differential g-protein coupling
hf ; vt ; beat-to-beat QT intervals
biventricular dysfunction ; isolated HeartMate
tug test ; COPd ; CHF ; cRF
pressure-overload-induced heart failure
social mandate ; accountable
hemodynamically unstable ; cPR
isoproterenol ; cXL-1020 ; myocytes ; hearts
cardiac angiogenesis ; coronary perfusion ; cardiac fibrosis
heart failure ; ventricular tachycardia
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
exercise intolerance ; chronic hff ; qol
energy substrate metabolism ; working hearts ; aac
evidence ; schfi
rule ; CAD ; CAD
diabetes mellitus ; cardiovascular disease ; baseline
cvd ; psoriasis
exercise ; haemodynamic ; pulmonary
rule
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; tNF ; nbDMARD
acs ; MT ;VAD
general hospital ; cardiac specialty hospital ; south dakota
medical records
ecmo ; egFR ; egFR
administration ; trastuzumab-related CHF
hf

hospitals
multicenter
sudden cardiac death
cachexia ;RV function ; body composition
hospital mortality
hospital length ; rehospitalization
cognitive impairment

natriuretic peptide levels ; biomarkers ; point of care
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
Spironolactone ; hyperkalemia ; kidney injury
bNP ;PAD ; bNP ; hh
sympathetic ; parasympathetic activity ; hf
eh ; systolic blood pressure ; renal impairment ; hypertension
exercise training ; ambulatory HF
mouse ; hh ; transition ; LV hypertrophy ; hh
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV assist device implantations ; heart failure admissions
chronic myocardial ischemia ; heart failure
HFpEF
mechanical cardiac support ; renal function ; heart failure
medical revascularization
baseline hgb ; exercise training ; kccq
Morpholino-based knockdown ; nucleolin ; protein expression
derive ; rule ; CAD ; systolic HF
technique ; sternotomy ; cardiopulmonary bypass
ms ; medical ; hf ; MS ; dynamic ; medical
parasympathetic function ;HF
medical ;HF ;HF ; ms ; reversed ; mva
jugular venous pressure ; peripheral oedema
Heart failure ;HF ; condition
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Fontan circulation ; sVR index ; cardiac index
isolated lVAD ; biventricular
mineralocorticoid receptor antagonists
medical ; congenital abnormalities ; heart ; nontraumatic death
Font circulation ; skeletal muscle mass ; metabolic
isolated HeartMate II lVAD
evidence-based
health insurance ; health system ; u.s. Food and Drug administration
cutoff value ; NT-probNP testing ; ED ; acute heart failure
blacks ; hypertension ; diabetes ; etiology ; socioeconomic status ; whites
albumin levels ; lVAD
Cytoscape ; daVID
cardiovascular conditions ;HF

emd
right heart circulation ; right heart failure
Raf-MEK1/2-erk1/2
MI ; late-onset ; MI ; hh
bisphosphonate ; heart failure
costs


Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac
diagnose ; heart failure ; preserved ejection fraction ; doppler echocardiography
heart failure ;HF ; Heart Failure adherence ; retention trial ;HARt
HF ; preserved ejection fraction ;HFpEF ; hypertension
NYha ; functional class ; quality-of-life score
Myocardial infarction ; left anterior descending coronary artery occlusion
hfpEF ; breathlessness ; fatigue
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
Î²-Blockade ; cardiac angiogenesis ; heart failure ; veGF
myocardial ischemic events ; cardiac resynchronization therapy
report ; aortic valve surgery ; post- lVAD
unloading ; heart ; isolated HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; medicine ; atheromatous coronary disease
Heart failure ;HF ; Latin America ; lla ; health service planning ; hf
rehospitalization ; medicare ; discharged
hf ; ct ;hazard ratio
palliative
hfpEF ; medical ; physical
oxidative stress ; GTPase Rac1 ; activity ; hearts ;ANS mice
circulating mediator of insulin resistance ; monocytes ; inflammatory stimuli
cardiovascular death ; urgent cardiac transplant ; death
medications ; outpatients ; heart failure ; NCDR PINnaCLE
beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
readmission rate
transformed
Intravenous iron ; heart failure ; iron deficiency
art failure ; Emergency department ; ed ; ed
conditions ; maladaptive remodelling ; heart failure
non-ischemic ; ischemic heart failure
psoriasis ;UV
RV dysfunction ; weight loss ; abnormal body composition ; hf


diastolic dysfunction ; hff
Î²-Adrenergic receptor blockade ; mortality ; heart failure ;HF
right ventricle overload leads ; stroke volume ; left ventricular ejection time ; lVET
NT-probNP ; hh ; immunoprecipitation ; mass spectrometric
Chromatin-associated proteins ; chromatin ; DNA ; gene expression profile
pd ; complications ; therapy ; hf
pulmonary hypertension ;PH ; heart failure
robot-assisted gait therapy ; Lokomat ; system ; heart failure
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
et ; HDl function ; et ; CHF-NYha-IIIb ; HDl function
Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
exercise ; hemodynamic status
lVET ; death ;ICU
congestive heart failure
aim ; implantable ; cardioverter-defibrillator deactivation
mitochondrial ; sarcomeric microstructure
heart failure ; ejection fraction
gut ; inflammation ; heart failure ; heart failure
pp ; acr ; CMS
mortality ;LCx ; LAD
CHF ; emergency department ; ed ; intubated
CHF ; activated neurohormonal systems
zSF1 ; heart failure ; ejection fraction
follow-up after discharge ; death ; readmission ; heart failure
heart magnetic resonance imaging ; chelation choices ; compliance ; heart disease ; thalassaemia
arterial tonometry ; VET ; precapillary PH ; heart failure
cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
line ; mutant mice ; hand2 ; heart muscle cells ; pathological hypertrophy
transoesophageal echocardiography ; patent ; thrombosis ; migration
uptitration ; heart rate ; renal function ; spironolactone
dialysis ; echocardiographic outcomes
microRNAs ;miRNAs ; heart failure
paradigm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
ambulatory HF ; ventricular ejection fraction
white rabbits ; renal DNx ; CHF
QT variability ; qt ; repolarization lability ; qt ; cardiac death
Beta-blocker dose ; HR ; bpm
mri ; tidal respiration ; myocardial t1 ; swine ; heart failure
cardiovascular disease ; baseline
advantage ; poc technology
psoriasis ; cardiovascular disease ;CVd
hospital ;AMI mortality rates
readmissions

Rhythm control therapy
cutoff ;septal
costs
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
LV diastolic dysfunction ; filling pressures ; doppler echocardiography
Cardiac magnetic resonance postcontrast ; heart failure ; ejection fraction
myocardial collagen ; collagen ; titin isoforms ; phosphorylation
RAS-blocker uptitration ; hFrEF ;HFpEF
Hemoglobin ; exercise ; health status ; chronic heart failure ;HF-action
systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
Plasma samples ; hh
pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic
heart failure ; ccnka sNP
GDm ; control group ; GDm ; BAT
baseline ; HR
transduction pathways ; proteins
alendronate ; alendronate ; heart failure
cardiovascular disease ; dRS
index admission

beta-blocker therapy
heart failure ; bisphosphonates
frailty ; heart failure ;HF
miRNAs ; cardiac remodeling ; heart failure
medical ; hf
diastolic dysfunction ; mortality
AlphaLISa ; immunoassays ; NT-probNP
Fontan ;SAF ; catheterization
death ; biological phenotype
sinus rhythm ; antiplatelet agents ; anticoagulants
implantable ; cardioverter-defibrillator deactivation
heart failure ; left ventricular ;LV ; ejection fraction
cardiotoxicity ; doxorubicin ; anti-neoplastic agent ; cancers
acs ; oHT ; transplant ; MT ;VAD
natriuretic peptides
RAS- ; Î²-blocker dose
Î²-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
hf ; rheumatoid arthritis ;RA
expression ; Bax ; bcl-2 proteins
financial ; hospital rates ; hf ; CMS ; conditions
regulation of feeding ; nutritional ; anti-inflammatory effects ; CHF
drugs ;HF ; ejection fraction ;HFrEF
hyperkalemia ; kidney injury ; spironolactone
Renal denervation ; dnx ; CHF
MT ;VAD groups ; aCS ; operations
refractory congestive heart failure ; peritoneal dialysis
Mammalian enabled ; mena ; regulator ; cytoskeletal actin dynamics ; heart failure ;HF
heart failure ; left atrial pressure ; hospital admission
Heart failure ; preserved ejection fraction ; hff ; cardiovascular reserve
diastolic dysfunction ; figure ; mechanism ; hff
follow-up ; discharge ; physician continuity ; heart failure
ambulatory iCD ; mortality
arni inhibitors ;angiotensin-receptor neprilysin inhibitors
Gastrointestinal bleeding ; ventricular assist devices
nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
myxomas ; cardiac benign tumors ; left atrium
fes ; ejection fraction ; hpf
bNP ; NT-probNP ; coronary artery disease ;CAD
exercise
NT-probNP
ect
aerobic capacity ; left-hand grip strength ; body weight ; waist circumference
Process redesign
myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
functional mitral stenosis ; ms ; ring annuloplasty ; ischemic mitral regurgitation ;MR
ICU ; admission ; precapillary PH ; heart failure
heart failure-related hospitalization ; left ventricular ejection fraction
Heart failure ; preserved ejection fraction ; hpEF ; cardiovascular morbidity
tissue doppler imaging ; left ventricular filling pressure ; systolic heart failure
lean ; zSF1 ; obese ; zSF1 ; diabetic
heart failure ; preserved ejection fraction ; hff
Kansas City Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
activating myocardial pde2 ; intracellular antiadrenergic ;HF
benefits ; spironolactone
follow-up ;HF
ii ; heart failure ; hh ; death ; cRT-d
pharmacologic
mechanical dyssynchrony ; QRs ; cRT
coronary occlusion ; collateral growth ; stent occlusion
carotid ; intima-media ; psoriasis
transfusions ; heart disease
combination ; exercise ; diet ; peak VO2 ;joint effect
PVf ; pb ; recovery period ; BP
chronic heart failure ; Hungary
RV dysfunction ; cardiac cachexia
remote monitoring ;RM ; heart failure
ecg ; ct
sst2 ; BB ; cardiovascular event rate
breast cancer ; trastuzumb-related CHF
hf ; emd ; dyssynchronous failing heart
acute heart failure ; aHF ; heart failure ; hf
angiogenesis ; post-myocardial infarction heart ; heart failure
aldosterone antagonist ; heart failure
surgery ; medical ;HF ; hypertension ; vasodilators ; diuretics
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HR ; beta-blocker therapy
pde2 ; hearts ; Î²-AR stimulation
psoriasis ; atherosclerosis ; cardiovascular events ; psoriasis
heart disease
heart failure
egFR ; diuretics ; hypertension ; ESRD
trastuzumab ; CHF ; nontrastuzumab
EO-cFUs ; mortality ;hazard ratio
point-of-care systems ; np ; ed ; outpatient settings ; acute heart failure
heart failure ; ejection fraction ; myocardial infarction
multicenter ; lVAS
black race ; hf ; cardiovascular mortality
exercise ; health benefits ; cardiac disease ; heart failure
hff
HF cPGs
HF ; risk factors ; fit ; HF mortality
HDl function ; CHF ; eth
coronary artery disease ; systolic heart failure ; etiology
implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
ea ; arterial compliance ;TAC ; end-systolic elastance ; ees ; baseline
biventricular support ; HeartMate II lVAD ; centriMag rVAD ; mortality ; hospital discharge
Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ; caBG
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hfpEF
baseline ; isoprenaline infusion ; SDQT ; hNorm ;HF
renal dysfunction ; all-cause mortality ; cardiovascular events ; primary isolated caBG
Pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
egf ;VAD ; ecmo ;VAD ; ecmo
CHF ; international Classification of Diseases
RV dysfunction ; body mass index ; fat mass index ; cachexia
baseline ; cRF ; HF mortality risk ; HF
Robot-assisted gait therapy ; LokomatÂ® system ; heart failure
cardiac growth ; disease recapitulates ; chromatin remodeling
idiopathic dilated cardiomyopathy cohort
dopamine ; nesiritide
medline ;EMBAse ; cochrane ; technical

HF ;HF
baseline ; ea ; TAC ; HR ; ees
care management ; telehealth technology ; health outcomes ; Medicare
ERC ; epicatechin ; muscle function
biomedical
myocardium ; expression ; pka ; downstream signaling
atrial fibrillation ; carvedilol ; metoprolol
grounded theory ; heart failure ; implantable cardioverter-defibrillator
MS ; valve plasty ; degenerative MR ; LV ; disease
HeartMate II ; biventricular ; HeartMate II implantation
end stage heart failure ; Heart failure ; public health ; europe ; north America
MIs ; Killip class ; conditions
heart failure ; mechanical ; cards-cardiovascular surgery Consensus report ; Heart failure
elastic N2Bus segment ; pevk
self-Care of Heart Failure index ; schf ; psychometric profile
proteomics ; detergent ; disease
HeartMate ; left ventricular assist system ; lvas ; heart failure
Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; mechanism of cardioprotection
pharmacologic ; acute HF ; chronic HF
arterial elastance ; pulsatile afterload ; heart
cXL-1020 ; hno ; inactive ; cXL-1051
tNF antagonists ; hf ; hospital admissions ; nbDMARDs ; RA
ejection fraction
grls ; hz ; cv
exercise ; diet ; exercise
mortality
benefits ; magnet

hf ; drug treatment ; PAf ; biosynthetic enzymes ; lyso-paf-AT
epidemiology ; myocardial infarction ;mi ; heart failure ;HF
cardiac magnetic resonance imaging ; invasive hemodynamic assessments ; baseline
Heart rate reduction ; exercise performance ; onset heart failure ; ejection fraction ; beta-blocker hypo-response
RAS ; hypertension ; nephropathy ; congestive heart failure
admission ; serum levels ; brain natriuretic peptide ; bNP ; creatinine ; natremia
multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
baseline ; NT-probNP ; MR-proanp ; MR-proadm
isoelectric focusing ; RIÎ± ; ser77 ; ser83 ; vivo phosphorylation sites
SDt ; SD ; rr intervals ;SDr ; qt ; heart rate variability
ucs ;septal ; QRs
Logistic regression models ; outcome ; death
IVc occlusion ; co ; twist ; apical rotation ; RS ; RS synchrony
readmission rate ; hospital stay ; congestive heart failure ; united states
diuretics ; morbidity
readmission rate ; heart failure ; follow-up visits
devices ; gastrointestinal bleeding
ms ; cardiac events
egf ;VAD ; ecmo ;VAD ; renal function
sst2/low-dose BB ; sst2 ; high-dose BB
CHF ; ed ; CHF ; intubated
physical ; mortality ; hf ; noncardiologist
zebrafish ; nucleolin ; genomic reprogramming
LV ; ejection fraction ; pcwp
hf ; am ; mortality
acute heart failure ; Collins
cardiopulmonary exercise ; muscular strength ; peak quadriceps force
public health ; air pollution ; cardiovascular health ; lead
ecg ; accessory pathways ; ion channelopathies ; cardiomyopathy
idiopathic dilated cardiomyopathy ; tuscany
hf ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
Morbidity ; mortality ;HFpEF ;HF ; EF
HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ;keletal muscle
heart failure ;HF ; inpatient ; outpatient
molecular biomarkers ; pathophysiology ; chronic HF
carvedilol ; metoprolol ; heart failure
erythropoiesis-stimulating agents ; anemia ; heart disease
intravenous iron ; exercise tolerance ; heart failure
report ; mitral valve plasty ; mitral regurgitation
costs ; QuÃ©bec health insurance board ; costs ; Ontario case costing Initiative
bet ; bromodomain-containing protein 4 ;brd4 ; cardiac tissues
RAS ; neprilysin inhibition ; change ; chronic heart failure ; systolic dysfunction ; treatment
change ; readmission rate
heart failure ; mechanical cardiac
economic ; lVAD
multiparametric echocardiographic score ; ct
ejection fraction
af ablation
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; ejection fraction
administration ; gadolinium-chelate contrast agent
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
Medicare ; inpatient data ; hf ; admissions ; acute care hospitals ; united states
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
low-dose dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; ROse ; acute heart failure
report ; DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure ; baseline
mouse ; hh ; salt loading ; uninephrectomy ; ANG II infusion
benefits ; hf ; ejection fraction ; pEF
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat ; metabolic risk
echocardiographic predictors ; cardiac resynchronization therapy ; crt
baseline serum creatinine ; serum potassium level
chromatin subproteomes ; heart failure ; mechanisms ; chromatin structure
Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion genes ; Retn
anemia ; chronic heart failure ;HF
university of Connecticut Heart Failure Center ; cardiologist ; heart failure
NT-probNP ; antibodies ; nonglycosylated
RV ; intrinsic left ventricular dysfunction
pdp ; weight loss ; diuretic response ; peripheral edema
Chronic heart failure ; transforming growth factor ; functional ; atrial explant-derived
HFpEF ; kccq ; health status
HeartMate II lVAD ; CentriMag rVAD
exercise ; heart failure
hf ; MI ; ejection fraction ;EF
inpatient admissions ; emergency department ; ed
nbDMARD ; tnf ; baseline covariates
trastuzumab ; cardiotoxicity ; congestive heart failure ; chf
pyridostigmine administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
uPR effectors ; protein kinase ; er kinase ;perk ; calreticulin ; chop ; hz
myosin binding ; protein-c phosphorylation ; ser23/24 ; troponin I phosphorylation ; hz
echocardiographic measures ; natriuretic peptide ; inflammatory markers
Phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
carvedilol ; thromboembolic events ; heart failure ; Î²2-receptor haplotype status
hFrEF ; exercise performance ; resting ; HR ; beta-blocker therapy
baseline ; PAf ; activity ; metabolic enzymes ; heart failure
XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic acf
rcts
cox hazard models ; ESRD ; death ; ESRD ; death ; ESRD
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold
heart failure ; heart failure ; nurses ; follow-up ; cardiology services
hf ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
cardiac deaths ; atherosclerotic CAD
surgery ; rheumatic ; MS ; mva
women ; health Initiative ; hf
infarcted animals ; left ventricle ; end-diastolic pressure ; hg
RV ; pathophysiologic mechanisms ; RV dysfunction
dialysis-dependent ;HF ; ct implantation
Peak oxygen consumption ; oxygen pulse
economic ; NHs ; behavioural-change ; chronic disease ; exercise
post-hct CHF ; hct ; city of Hope

pigs ; vena cava ; icc ; snared ; co
doxorubicin ; ip ; induction of serum resistin levels ; Hum-retn mice
costs
CHF

aldosterone receptor antagonists ; mortality ; systolic heart failure
scn5a ; uPR ; downregulation ; cardiac genes ; hz
east ; rhythm control therapy ; af ; cardiovascular complications ; AF
albumin levels ; nutrition ; inflammation ; hepatic function ; lVAD implantation
right ventricular ;RV ; left ventricular assist device ; lVAD
pasp ; downward regression line shift ; nonsurvivors ; PASp ; tAPse
cox proportional hazards
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ;cc
non-fatal stroke ; heart failure
hearts ; mena ; cardiac injury ; mena ; hh pathophysiology
biomarkers ; molecular dysfunction ; chronic HF
ST2 ; discrimination
gls ; index beat method ; cv ; cox
Genes ; non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
VAD ; ecmo ; ecmo
Ambient air pollution ; cardiovascular health ; trigger ; acute myocardial infarction
kccq ; kaplan-meier curves ; death
RAS ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
testosterone therapy ; exercise rehabilitation ; chronic heart failure ; testosterone status
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
AMI ; heart failure ; kidney infection ;UTI
proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
icc ; multicenter Automatic Defibrillator implantation ; trial-Cardiac resynchronization Therapy
Olmsted County ; Minnesota ; MI ; hh
health Buddy ; admissions ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
collected ; medical hospitalization ; hh
odds ratio ;hazard ratio ;HF ;AMI ; admission ; discharge
neurohumoral blockers ;HF
left ventricular ejection fraction ; long-term mortality ; heart failure ; Heart Failure Survey ; israel
inhibition of vascular endothelial growth factor ;veg ; transition ; compensatory hypertrophy ; cardiac failure
rule ; CAD ; CAD
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD ; implantation
apoptosis ; pathogenesis ; heart failure
diagnose ; follow-up
diuretic efficacy ; neurohormonal activation ; fluid overload
uPR ; mRNA splice ; cardiac ; hz
LVEF ; LVEF
evidence ; lVAD ; transplantation eligibility status ; budget
BETs ; transcriptional pause release ; transcription ; pathological stress
eCG ; atherosclerotic CAD ; cardiac death
hf ; index AMI ; adjusted hazard ratio ; mortality
ct-d ; IE ; defibrillator-only therapy
HR dynamics ; HR ; risk stratification
cardiopulmonary exercise testing ; echocardiographic assessment ; myocardial function ; left ventricular filling ; exercise
speckle tracking echocardiography ; ste ; BiVP ; right ventricular pressure overload ;RVpo
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
coronary revascularization ; hemodynamically stable ;ICU
obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
bNP ; hf ; bNP
perk inhibition ; full-length scn5a ; kv4.3 mRNA levels ; na+ channel mRNA splice
LVf ; mortality ; hospitalization ; acute decompensated HF
expression ; hf ; mena ; cardiac pathophysiology
salt loading ; uninephrectomy ; ang II infusion ; mouse model ; cardiac function ; hz
echocardiographic score ; LV ; reverse remodeling ; sensitivity
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
HR reduction
bottleneck stent ; myocardial infarction ; antiplatelet medication
vn ; mice ; LV ; lung weight
Font failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio
systolic heart failure ; spironolactone
rad variant ; q66p ; congestive heart failure
functional enrichment ; regulation of programmed cell death ; degs
atrial fibrillation ; treatment ; atrial fibrillation ; Stroke prevention trial
etiology ; comorbidities
financial ; evidence points ; intestinal morphology ; absorption function ; CHF
exercise ; anaerobic metabolism ; respiratory
arni ; cardiovascular mortality ; hospitalization ; heart failure
myocardial dd ; muscle strip stiffness ; titin hypophosphorylation
peak work rate ; peak quadriceps force
expression ; cardiac hypertrophy ; nucleolin
idiopathic dilated cardiomyopathy
readmission rates
NP measurement ; POc measurement ;NPs
benefits
Kansas City Cardiomyopathy Questionnaire ; kvq ; hh ; EF ; hhpEF
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure relationship ; heart failure ; index of right ventricular contractile function
biventricular ; hybrid system ; HeartMate II lVAD ; centriMag ; right ventricular assist device ; rad
Blood pressure ; arm cuff ; stroke volume ;SV ; ejection fraction ; end-diastolic volume ; echocardiography
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic
sNP ; ka renal chloride channel gene ; ccnka
exercise training ;HF ; exercise training ; therapy
contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
NT-probNP levels ; plasma ; dyspnea ; left ventricular dysfunction ; admission ; ED
pathological remodelling ; heart ; cardiac hypertrophy ; hf ; death ; fibrosis ; inflammation
hz-action cohort ; baseline hgb ; baseline HRQol ; kccq
circulating progenitor cells ; cps ; endothelial repair ; cardiovascular diseases
right ventricular ;RV ; body composition ; advanced heart failure ;HF
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
american college of Cardiology ;American Heart association ;RAS ;RAS
case report ; functional MS ; valve plasty ; degenerative MR ; LV
EO-cFUs ; cd34 ;vegFR2 ; cells ; mortality ; nondiabetic patients
implantable ; cardioverter-defibrillator deactivation ; heart failure
functional MS ; valve plasty ; annular size reduction ; MR ; LV ; dilated ; disease
heart failure ; hf
LV ; diastolic properties ; XO inhibition ; heart failure
SDt ; hwt ; hwt ; fixed-rate atrial pacing
borderline
technique ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
bNP ; inhospital mortality
ct-d ; heart failure
expenditure ; health per capita ; income per capita ; hf ; la
bt ; dt ; bt
af ; pharmaceuticals ; hff
blood pressure control ; lipid-lowering therapy ; smoking cessation ; foundation ;RAS
costs
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
implantable cardioverter-defibrillators ; iccds ; cardiac resynchronization therapy ; crt
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
low-sodium DASh ; diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
diagnose ;HFpEF ; echo-doppler cardiography ; haemodynamic assessment
RAS- ; Î²-blocker uptitrations ; hFrEF ;HFpEF
exercise-induced PASp ; hg ; PASp
skeletal muscle ; heart failure ; diabetes ; epicatechin-rich cocoa
physical ; hf
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
eplerenone ;HF-ref ; inducing hyperkalemia ; wRF
mitochondrial complex ; activity ; post-aac ; ratio of phosphocreatine ; ATP
sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
frail ; intermediate frail
QRs morphology ; cardiac resynchronization therapy ; crt
hff ; outcome-monitoring ; cardiac event
RM ; discharged ; admission ; heart failure
acute heart failure ; aHF
embryonic gene programs ; pathological heart disease ; transcription factors
mdc
LBb ; implantable cardioverter defibrillator-ct ; primary outcome
isolated heart rate ;HR ; ivabradine ; afterload ; systolic heart failure
cardiovascular death ; stroke ; heart failure ; myocardial infarction
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical ; heart failure
Cardiac-resynchronization therapy ; cmt ; chronic systolic heart failure ; QRs
perk activation ; scn5a ; kv4.3 ; mRNAs ; transient receptor potential cation ; m7 ; tm7 ; channel mRNA
implantable cardioverter-defibrillator ; Heart function Clinic ; university health network ; toronto ; Canada
exercise-induced PASp ; pulmonary hypertension ; ventricular contractile reserve
MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
biomedical treatment ; chm ; biomedical treatment ; dm ; heart failure
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
Cardiovascular ; Renal Atherosclerotic lesions ; coRAL ; stenting ;RAS
mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;icds
left-to-right interatrial shunting ; heart failure ; ejection fraction
Mediterranean and Dietary approaches to Stop hypertension ;DASh ; diet scores ; mortality ; postmenopausal women ; hh
multiparametric echocardiographic score ; reverse remodeling ; ct
Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; beats ; heart failure
antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
HF ; HF ; epidemiology ; SH ; rheumatic fever
mortality ; readmissions ; costs
caloric restriction ;diet ; aerobic exercise training ; exercise capacity ; QOL ; obese ; hff
chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; interconnected molecular pathways
medications ; heart failure ; ejection fraction ; outpatient setting
hfpEF ; diastolic filling time ; heart rate
mice ; cardiac myocyte-specific Mena overexpression ; tgtetMena ; cardiac pathology
antiplatelet agents ; anticoagulants ; vascular diseases
international right Heart foundation working group ; step ; right heart failure
poc systems ;NP
LBb ; QRs ; implantable cardioverter defibrillator-ct
echocardiography ; cardiac diameters ; cardiac function
electronic ; medline ;EMBAse ; PsycINFO
functional capacity
medical center
systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
af ; heart failure ; financial burden
follow up ; body weight ; FM ; fm ;cc
r. Cluster
left ventricular ejection fraction ; left ventricular diastolic end diameter
eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
left ventricular ejection fraction ; heart failure ; preserved ejection fraction ; hpEF
Î²-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
baseline ; hgb ; baseline ; kccq ; hgb ; exercise training ; HRQol
heart failure ; hospital discharge ; readmissions
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; cardiac index
myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous HF
ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
truncated na+ channels ; unfolded protein response ; ucp ; scn5a ; electric remodeling ; hh
intermacs ; interagency Registry for mechanically assisted Circulatory support
allopurinol ; LV ; contractile function ;ROS ; myofilament ; sensitivity
techniques ; systolic function ;HFpEF ; long axis function ; exercise
physicians ; advanced heart failure
hf ; mortality ; hazard ratio ; mortality
hf ; hyperkalemia ; hypokalemia ; spironolactone ; derive
receptors ; g-protein-coupled receptor kinase-2
NT-probNP assay ; glycosylated
scn5a ; angII ; hypoxia ; expression ; induced ; uPR
isolated heart transplant ; ect
bNP ; diastolic dysfunction
median rate ratio ; treatment ; comorbidities
Medicare ; claims ; Medicare ; post-acute care transfer policy
heart failure ; compliance ; etidronate ; alendronate
metabolic exercise ; cardiac ; kidney index score
physical activity ; cRF ; hh mortality
et ; molecular pathways ; chronic heart failure ; ghf
dopamine ; nesiritide ; renal function
anemia ; iron deficiency ; MEDline ; cochrane Library
kccq ; internal consistency ;HFpEF ; ronbach
implantable cardioverter defibrillator-crt ;LBb
principal mechanisms
follow-up times ; alendronate ; etidronate ; raloxifene
chemotherapy ; trastuzumab ; CHF ; international classification of Diseases ; healthcare common procedure coding system codes
heart failure ;HF ;HF ; left ventricular ejection fraction ;LVEF
hART ;HFpEF ;HF ; ejection fraction ;HFrEF
conscious dogs ; hz ; cXL-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
bone morphogenetic protein ; expression ; rRNA transcription ; shift ; heterochromatic chromatin
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
elevated resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure
extracellular matrix ; left ventricular biopsies ; tissueFAXs technology
systolic HF ; Danish Heart Failure ; ESRD ; Danish Registry on dialysis
left ventricular assist devices ; lVADs ; heart failure ; pump dysfunction ; pump replacement
ST2 ; natriuretic peptide
biventricular pacing ; biVP ; cardiac output ; co ; cardiac surgery
magnetically levitated lVAS ; mortality risk ; Seattle Heart Failure
New York Heart association ;NYha ; chronic heart failure ; ejection fraction
AlphaLISa immunoassays ; antibodies ; circulating ; NT-probNP
creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; regulation ; rad q66p ; rGK protein
Myocyte hypertrophy ; heart failure ; gene expression ; DNA
change
biomedical treatment ; chm ; biomedical treatment ; dm ; heart failure ; PubMed
sst2 ; high-dose BB ; sst2 ; low-dose BB ; odds ratio ; cardiovascular
neurohormones ; adipokines ; body composition ;cc ; fat free mass ; fm ; fat mass ;FM
cardiac plasma membrane ; s1p1 ; overstimulation ; heart failure
Sprague-dawley rats ; sham ; acf ; allopurinol
myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin ; follow-up
catheter ablation ; AF ; hff ; left ventricular ; ejection fraction
BB therapy ; sst2 measurement ; chronic heart failure ; BB
ct ; hazard ratio
ESRD ; outpatients ; systolic HF ; egFR
passage ; length-force relationship ; step ;RV ; LV
tunel assay ; apoptotic cells ; tunel-positive cells
functional efficacy ; hno ; donor ; myocardial function ; first-in-man evidence ;HF
biventricular ; rVADs ; explanted
transitions ; readmission rate ; congestive heart failure ; midwestern state ; South dakota
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium ; conditions
transplantation ; consultation ; MT ; consultation ; operation
transplantation ; LV assist device implantation ; heart failure
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
intraclass correlation coefficient ;ic ; kappa coefficient ; change ; mdc
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
race ; exercise training ; chronic heart failure ; Heart Failure ; exercise TraiNing ;HF-action
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ; preserved ejection fraction ; hff ; heart failure ; overweight ; obese
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
renal dysfunction ; heart failure ; hz ; renal disease ; erd
echocardiographic score ; LV ; reverse remodeling ; LV ; end-systolic
Peripheral artery disease ;PAD ; heart failure ;HF ; hh ;PAD
readmission rates ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Font circulation
biological
SDt ; hwt ; hNorm ; Î²-adrenoceptor blockade ; esmolol
Cardiology ; national Cardiovascular Disease Registry ; clinical Excellence
sts HH ; medical ; all-cause mortality ; discharged ; patients ; heart failure
induced myocardial infarction ; heart failure ; bisoprolol ; vehicle
transitions of care
CHF ; cardiac explant
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-inv
report ; hno donor ; cXL-1020) ; isolated myoctyes ; intact hearts ; heart failure ;HF

ms ; subvalvular ; dynamic ; ms ; fixed ring
race ; chronic heart failure ;HF ; exercise training
histological ; capillary ; coronary perfusion
internists ; cardiologists
shuttle walk test ; body mass ; hand grip strength ; baseline
protocol-driven POc testing ;NP ; consultation ; ED
heart failure ; CHAr programme ; candesartan in Heart Failure assessment of reduction in Mortality and Morbidity
Troponin ; natriuretic peptide ; biomarker ; heart failure ; atherosclerosis
left-to-right interatrial shunting ; heart failure ; ejection fraction
physical ; bmi ; heart rate ; rhythm ; lying ; standing ; blood pressure ; auscultation ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance ; pathobiology ;pathophysiology
aldosterone antagonist therapy ; chronic advanced heart failure ; post-myocardial infarction ; heart failure
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin ; cardiotoxicity
heart failure ; left ventricular ejection fraction ; spironolactone ; Kaiser Permanente Northern California
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; coronary artery bypass grafting
septum ;systolic ; LV ; posterior wall ; LV ; internal diameter ; metoprolol
american college of Physicians ; acp ; evidence ; anemia ; iron deficiency ; heart disease
hff ; caloric restriction ; aerobic exercise training ; peak VO2
economic ; Heart failure ; cost-effectiveness model ; cost-effectiveness ; disease management ; heart failure
HF registry ; HF ; hf ; hfpEF
BAT ; n-terminal pro-brain natriuretic peptide ; hh
HR variability ; mortality ;AMI ; CHF ;LV dysfunction
exercise ; cell senescence ; active ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
cardiac transplant ; ect ; transplant pool ; transplant
Fontan ;PF ; catheterization
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; anoop Shah ; air pollution ; heart failure
anemia ; HF ; health-related quality of life ; hQol ; HF
cell therapy ; chronic heart failure ; ghf ; disease
dyssynchronous nonfailing ;HF ; canine electromechanics
rv failure ; chronic pulmonary arterial hypertension ; pah ; pulmonary embolism
rv ; pulmonary embolism ; mortality
serum resistin ; women ; anthracycline-containing chemotherapy ; cardiotoxicity
sst2 ; high-dose BB ; cardiovascular event rate
rad q66p ; cardiomyopathy
ventricular ; fiber ;sheet orientation
baseline ; SDQT-to-SDr ratio ; hwt ; hwt
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
exercise ; medical Therapies ; Cardiac Function ; Breath ; Lung congestion
electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; left ventricular ejection fraction
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol
cardiac resynchronization therapy ; ct ; heart failure ; hz ; QRs ; ejection fraction ;EF
Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ;LAD
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
spironolactone ; death ; hyperkalemia ; kidney injury
mortality ; mortality ; cardiovascular mortality ; hh ; race ; cox models ; exercise training
neprilysin inhibitors ; natriuretic peptide system ; breakdown ; atrial natriuretic peptide ; natriuretic peptide
pip relationship ; nonsurvivors ; hff ; hfpEF ; resolution
HF-action ;HF ; ejection fraction ; exercise training
writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac
NT-probNP levels ; mortality ; hh
haematopoietic cell transplantation ; ht ; congestive heart failure ; chf ; ht ; anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; administration ; doxorubicin
in vivo inhibition ; mir-25 ; antagomir ; cardiac dysfunction ; murine myocardium ; heart failure
Chinese herbal medicine ; ghm ; adjunctive treatment ; dilated cardiomyopathy ; dm ; heart failure
hypertension ; hg ; diabetes mellitus ; systolic ; diastolic murmurs
hypoalbuminemia ; albumin concentration
bundle branch block ; electrical activation ; dyssynchronous heart failure ;HF ; electromechanical ; heart
heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
Baroreflex sensitivity ; time domain ; heart rate variability ; hv ; CHF-inv ; sham-inv ; sham levels ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
nurse ; cognitive impairment ; hospitalization ; discharge ; heart failure
carvedilol ; Î²-blocker ; Î²-blocker ; metoprolol ; thromboembolic events ; heart failure
baseline ; cardiac transplant ; ect
hz ; am ; pna ; mortality
heart failure ;HF ; HF
arrhythmia substrate ; am ; HR ; arrhythmia events
doxorubicin-induced cardiotoxicity ; Hum-retn mice ; littermate ; resistin ; rte
hypertension ; hff ; DASh ; srd ; sodium ; kcal
emd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; hfpEF ; non-diastolic abnormalities ; cardiovascular function
ejection fraction ; cardiac index ; inotropes ; medical ; transplant
high-density lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ; nitric oxide
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
degs ; non-ischemic ; ischemic heart failure ; heart failure
insulin resistance ; diabetes ; insulin receptor substrates ; irs1 ; irs2 ; insulin-signaling ; cellular metabolism
admission to discharge ; older adults ; heart failure ;HF ; Nursing outcomes Classification ;noc
8-fluo-cAMP binding ; phosphomimic ser77 ; ser83 ; mutant ; RIÎ± proteins ; double mutant ; wt RIÎ±
albumin ; mortality ; lVAD implantation ;hazard ratio
systolic heart failure ; QRs duration ; ct ; rate of death ; hospitalization ; heart failure ; mortality
cox regression models ; propensity score ; oral glucocorticoid ;HF ; loop diuretics
functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; heart failure ; impaired systolic function
dialysis ;HF
bleeding ; driveline infection ; gastrointestinal bleeding ; stroke ; Rankin Score
Beta blockers ; readmissions ; heart failure ; ejection fraction ; hf ; heart rate ;HR
dyssynchronous HF ; electromechanical delay ; emd ; myocyte depolarization ; myofiber
QRs ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; ambulatory Heart Failure trial ;RAFt
biomarker studies ; biomarker-guided clinical trial
SAF ; abnormal liver texture ; nodularity
transplant ; pd ; hf ; volume management ; post-PD initiation
weak grip strength ; physical exhaustion ; activity ; unintentional weight loss
ct-d ; ii ; IC ; ct-d ; IEs
EDs ; discharge ; heart failure ; ED ; readmissions ; repeat ED visits
right heart failure ; refractory cardiogenic shock ; heart team ; corporeal membrane oxygenation ; ecmo ; cp ;ICU
report ; right atrial myxoma ; embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
heart disease ; hh
heart magnetic resonance imaging ; chelation choices ; compliance ; heart failure ; arrhythmias
ejection fraction ; ef ; pre-PD ; NYha ; class IIIb ; right ventricular dysfunction
cps ; e-cfus ; circulating ; vgf2
expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
evidence ; continuous-flow lVADs ; heartMate II ; hm ; HeartWare ; bt ; dt
baseline
skeletal muscle mass ; relative appendicular lean mass index ; z-score
DASh ; diet scores ; mortality ; hh ; diet scores
mortality ; mortality
bNP ; bNP ; inhospital mortality
cardiovascular diseases ; heart failure ; hz ; hz
heart failure ; left ventricular systolic dysfunction ; BB
ccnka polymorphism ; heart failure ; glomerular filtration rate ; reNAStur
ST2 ; functional capacity ; hh
cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; failing hearts
expression profiling ; cultured cardiomyocytes ; jq1 ; drug ; induction ; phenylephrine-induced genes
exercise-induced PASp ; right ventricular contractile reserve ; exercise-induced PASp
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; heart failure
cardiac ; insulin-resistance ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
baseline ; post-DASh ; srd ; brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic
Psychosocial factors ; exercise ; Heart Failure Patients ; Heart Failure ; exercise training ; hz-action
derivation cohort ; coronary angiography ; systolic HF ; etiology
arterial elastance ; end-systolic elastance ; ees ; ventricular-arterial coupling ; techniques
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
cells ; angiotensin II ; angII ; hypoxia ; activators ; scn5a mRNA splicing ; induced ; scn5a
evidence ;HF ; ejection fraction ;HFrEF ; HF ; ejection fraction ;HFpEF
bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; endothelial function ;HFpEF
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
intubation rates
raloxifene ; mechanism of action ; heart failure
hearts ;TTA ; tgtMena ; mice ; heart mass ; transgenic mice
hff ; exercise ; respiratory gas analysis ; baseline
drugs ; heart failure ; biomedical
wasting of fat ; lean mass ; fat loss ; adipose tissue ; cardioprotective ; hf
hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
black race ; chronic HF ; exercise performance ; HF ; mortality ; exercise training
adverse event rates ; acute myocardial infarction ; congestive heart failure
Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin ; hretn ;human resistin ; mRNA ; expression
lVADs ; CF ; HeartMate II ; Thoratec Corp ; Pleasanton ; calif ; hVAD ; HeartWare intl ; intl ; Framingham ; mass
FM ; plasma ;NPs ; adiponectin ; baseline ; FM ; fm ; nps ; adiponectin
sympathetic tone ; parasympathetic tone ; heart rate response ; metoprolol ; atropine
eh ; hfpEF ; pathophysiologically ; hf ; hf ; hff ; therapy
collected ;HF ; immunoreactive ; NT-probNP ; NT-probNP
beat-to-beat QT interval ; eCGs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine infusion

power spectral ; low-frequency ; high-frequency ;LF ;HF ratio ; CHF-inv ; sham-inv ; sham levels ; DNx
contractility ; ventricular-arterial coupling ; SV
follow-up visits ; readmissions ; hospital
natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
cardiac magnetic resonance ; hff ; biomarker ; hff
hz-action ; left ventricular ejection fraction ; New York Heart association ; hz ; exercise training
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 ; rats ; heart failure ; ejection fraction
transcriptional ; cardiac tissue ; mice ; jq1 ; vehicle ; bet inhibition ; pathological cardiac gene expression programme
negative binomial regression models ; health
systolic blood pressure ; left ventricular ;LV ; hypertrophy
conditional ; hand2 ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; induction ; fetal gene program
cutoff value ; admission ; NT-probNP ; ED ; acute HF
Peak oxygen consumption ;VO2max ; HR
follow-up ;heart failure ; noncardiac ; cardiac transplant
frailty ; health ABC short physical performance Battery ; hbc Battery ; Gill index ; hh
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; abrogate pathological gene expression ; hh progression
rule ; CAD ; angiography ; systolic HF ; cost
load-corrected chronotropic response ; heart rate ; exercise ; baseline ; follow-up tests ; heart rate ; exercise
hospital ; gastrointestinal bleeding ; ventricular tachycardia storm ; terminal heart failure
percutaneous revascularization ; angioplasty ; stenting
hz ; t2d ;ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
hz ; QRs prolongation ; LVEF ; ct ; reverse remodeling ; LV ; systolic dysfunction
vrv ; lVAD ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

frail ; Gill index ; hh
hf ; am
Chronic heart failure ; ghf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
Î²-AR stimulation ; catecholamine infusions ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac ; Î²-AR responsiveness
chronic pAH ; rv ; pharmacologic ; RV failure management ; pAH
zSF1 groups ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular
Xanthine oxidase ;XO ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ; acf
free-breathing pulse sequence ; myocardial t1 changes ; swine model ; tachycardia-induced heart failure
pf ; New York Heart association ; pf
medication
mortality ; physicians ; low-volume hospitals
western Australian ; administrative ; health ; hh ; am
report ; conditions ; Turkey
eds ; heart failure ; ed
science ; treatment ; hh
miRNAs ; noncoding RNAs ; expression ; binding ; messenger RNA
HFpEF ; ivabradine
cardiac c-Kit ; cells ; cardiac ; explant-derived cells ; cardiac functions ; myocardial infarction
NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
pathophysiology ; hf ; medical ; pathophysiologic state
heart failure ; hz ; acute myocardial infarction ;AMI ; pneumonia ; pna
mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
inhibitor jq1 ; bets ; chromatin ; downstream ; signalling ; RNA polymerase II ;Pol II
catheter ablation ; atrial fibrillation ; af ; heart failure ; preserved ejection fraction ; hff
heart failure ; ejection fraction ; hpEF ; health status
cox proportional hazards regression modeling ; ie ; hospitalization ; acute coronary syndromes ; coronary interventions
adenosine monophosphate ; cAMP ; cyclic guanosine monophosphate ; cgm ; hearts
RA ; methotrexate ; tnf antagonist ; non-biological disease ; antirheumatic drug ; nbDMARD
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
report ; ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor ; s1PR ; Î²1-adrenergic receptor ; g-protein-coupled receptors ; heart
septal ; pcwp
atrial fibrillation ; carvedilol ; metoprolol
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-inv rabbits ; sham-inv ; CHF-DNx
Nordic walking ; standard cardiac rehabilitation ; functional capacity ; heart failure
pharmacological ; device ; left ventricular function assessment
grs ; LVf ; sa ; cv ; echocardiographic systolic parameters ; af
ERC induced recovery ; DAPc ; sarcomeric microstructure ; Skm ; myofibre regeneration
signalling cascades ; microRNAs ; expression ; bHLh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
rad q66p ; inhibitory ; rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
EF ;LCx ; LAD ; stenting ; infarcted left ventricle ;LCx ; LAD
eh ; compliance ;LV ; end-diastolic volume ; LV ; end-diastolic pressure ; hg ; coefficient
mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
hART ; New York Heart association ;NYha ; hh ; self-management counseling ; primary outcome ; hh
cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; hh ; pathogenesis ; hh
blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
grade
hf
right heart circulatory failure ; mechanisms of disease ; right heart
voltage-gated ; ventricular action potentials ; trigger ; excitation-contraction ; coupling ; myocardium
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; ejection fraction ; hpEF
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
bp ; glomerular filtration rate ; hypertension ; transmitral ; e-wave ; diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; axis ; natural vasodilatory ; diuretic effect ; natriuretic peptides
Î²-blockade ; disease progression ; cAMP-dependent protein kinase ; pka ; downstream ; Î²-adrenergic receptor activation
erythropoiesis-stimulating agent therapy ; benefits ; venous thromboembolism
black race ; mortality ;hazard ratio ; cardiovascular mortality ;HF
chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
genetic ; CHF ; predictive model ; genetic
peak oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; hh index
heart failure ;HF ; tumor necrosis factor ; tf ; tNF antagonists ; HF
Centers for Medicare and Medicaid services ; cms ; publicly ; mortality ; readmission rates ; penalties
follow-up ; physician ; discharge ; death ; readmission
rule ; CAD ; diameter stenosis ; left main ; CAD ; CAD ; proximal left anterior descending artery
signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin
hff ; sodium-restricted DASh ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
mechanism ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular dilatation
Randomized aldactone evaluation study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortality
heart failure ; acute myocardial infarction ; acute myocardial infarction ; western australia
CHF ; ht ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication ; nonadherence ; salt
pathophysiological
lVAD ; albumin levels ; hypoalbuminemia ; surgery
creatinine ;hazard ratio ; post-transplant mortality
glomerular filtration rate
hm II ; HeartWare ; economic ; hm II
dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
HR variability ;turbulence ; HR variability ;turbulence ; cardiac patients
implantation ; lVAD ; transplantation eligibility status ; bt ; dt ; medical therapy
radial artery tonometry ; admission ; PH ;ICU
magnetically levitated centrifugal-flow chronic lVAS
eRK1/2 ; signalling ; signalosome complex ; scaffold protein drives ; kinases ; sequential phosphorylation
Breast cancer ; Medicare ; breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare
ejection fraction ; natriuretic peptide ; heart failure ; inhospital outcomes ; get with the guideline-Heart Failure Registry
cardiomyocytes ; pde2 activity ; cgm ; nitric oxide donors ; pde2 inhibition ; Î²-AR responsiveness
l-dko mice ; cardiac ; iRS1 ; iRS2 ; heart failure ; cardiac energy metabolism ; activation ; mitogen-activated protein kinase
HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-Î²II-Ser ; p70s6k-Ser
PASp
sts ; hh ; hm ; sts ; tm
mouse ; ventricular myocytes ; transient
administrative ; Alberta ; discharged ; hospital ; heart failure
heart failure ; histologically ; myocardial collagen ; heart failure
ct ; time to death ; hf ;hazard ratio ; LVEF
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1p ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1p1 ; cardiac gene therapy
relative risk ;RR ; heart failure ; bisphophonates ; crude ; RR ; adjusted hazard ratio ;HR
Medicare ; Centers for Medicare ; Medicaid services
guideline ; heart failure ; Clinical practice guideline ; cpg ; heart failure ;HF
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
kccq ; New York Heart association ; hfpEF ; hf ; EF
Rhythm control therapy ; af ; atrial structure ; sinus rhythm ; rhythm control ; rate control
acute heart failure ; renal dysfunction ; dopamine ; low-dose nesiritide ; renal function ; diuretic therapy
hf ; body composition ; skinfold thickness ; dual-energy x-ray absorptiometry ; echocardiography ; blood testing
heart failure
acp ; red blood cell transfusion strategy ; hemoglobin threshold ; hemoglobin levels ; coronary heart disease
heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia ; conditions
implanted ; left-to-right interatrial shunt ; haemodynamic ; heart failure ; ejection fraction
right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ; dt
Caloric restriction ; aerobic exercise training ; Peak oxygen consumption ; Heart Failure ; ejection Fraction
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-ct trial ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
Oral glucocorticoids ; hh
HR ; ivabradine group ; ea ;TAC
carvedilol ; metoprolol ;hazard ratio
ethnic groups ; chm ; adjunctive treatment ; dm ; heart failure
testosterone ; exercise ; health outcomes ; CHF ; testosterone status
change ; peak VO2 ; lean body mass ; change ; thigh muscle ;intermuscular fat ratio
get with the guidelines-heart Failure ; hf
economic ; Patient management ; Heart Failure ; cost-effectiveness model ; disease management ; heart failure
hfPSI ; medical ; hf ; outpatients ; hf ; health systems
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
multivariate cox model ; PASp ; exercise ; peak o2 per kilogram ;hazard ratio ; peak o2 per kilogram ; PASp
pathophysiology ; heart failure ; ejection fraction ; hff ; myocardial extracellular matrix accumulation
mechanism ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ;pvf ; implanted ; cardioverter-defibrillator device
rad ; rGK ; rem ; rem2 ; rad ; gem ;Kir ; monomeric g proteins ; ventricular action potential duration ; EC coupling gain ; cardiac ; activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hf ; myocardial infarction
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; Î²-blocker
Swedish web-system for enhancement and development of evidence-based care ; Heart disease ; Therapies registry ; primary isolated caBG ; sweden
LVEF ; reverse remodeling parameters ; time to death ; hh ;hazard ratio
brain natriuretic peptide ; bNP ; bNP ; bNP
coprimary end points ; cumulative urine volume ; decongestion ; change ; serum cystatin c ; enrollment ;renal function
tpacse ; longitudinal RV fiber shortening ; PASp ;force ; RV ; in vivo ;RV ; length-force relationship
pde superfamily ; pde2 ; cgm ; cAMP hydrolysis ; cross talk ; cgm ; cAMP signaling
probp ; np-probp ; midregional proanp ;MR-proanp ; adiponectin ; CHF ; bmi ; FM
re-hospitalization ; admissions
mitochondrial-targeted antioxidant ; Szeto-schiller ;SS ; SS20 ; cardiac function ; proteomic remodeling
financial ; cardiac arrest ; cardiopulmonary resuscitation ; cp ; posterior wall infarction ; cardiac
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ; hz
evidence ; acp ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin
uPR ; scn5a ; ventricular systolic HF ; induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; Î²-blockers ; mortality ; readmissions
financial incentives ; cochrane Effective practice ; organisation of care taxonomy
coPD ; CHF ; cRF ; icc ; kappa coefficients
stable heart failure ; left ventricular ejection fraction ; aerobic ; dynamic resistance training ; lower limbs
implantable ; cardioverter-defibrillator deactivation ; implant
heart failure ; myocardial function ; ventricles
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator shocks
left ventricular longitudinal systolic strain ; grs ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ;AF
mouse ; rad ; murine ; rad ; kv ; currents ; cav1.2 ; cav1.3 ; rad
MI ; hazard ratios ; hh
Medicare ; acute care hospital ; hh ; am ; pna
cardiovascular events ; baseline sst2 ; BB ; metoprolol succinate
ctnt ; NT-probNP ; aRIC HF model ; abcs ; NRIs
early-onset ; late-onset HF ; HF ; EF ; HF ; change ; HF ; MI
HDl ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
carvedilol ; von Willebrand factor ; metoprolol ; Î²2-adrenergic receptor haplotype
mouse heart failure ;HF ; hypertensive heart disease ; hd ; pathophysiology ; hd
sarcoplasmic reticular ;SR ; protein ; SR ; pump ; phospholamban ; infarcted hearts ; metoprolol
time up & go ; tug ; chronic obstructive pulmonary disease ; coPD ; chronic heart failure ; chf ; chronic renal failure ; crf
exercise ; intramuscular testosterone supplementation ; chronic heart failure ; chf ; low testosterone status ; health outcomes
hf ; LVEF ; long-term mortality ; LVEF ; LVEF ; long-term mortality
gls ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; cv
heart failure ;HF ; plasma ; natriuretic peptide ; bNP ; ejection fraction ;EF ; HF ; sex
RM ; home telemonitoring ; implanted monitoring devices ; medical ; ss ; contact ; hh ; human-to-machine interface ; hm
cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; acp ; shock therapy
ethically ; religious beliefs ; legal majority ; decisions
medical records
cost ; rhythm-control ; rate-control
left ventricular ejection fraction ; egFR
fit ; unfit ; cRF distribution ; hazard ratios ; fit ; unfit ; overweight ; body mass index ; obese
ct ; hazard ratio ; confidence interval
hfp ; blood urea nitrogen ; natriuretic peptide ; New York Heart association ; diabetes ; atrial fibrillation ;flutter
Medicare ; Patient safety monitoring system ; mps ; adverse event rates ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
cd34 ;vegFR2 ; cells ; functional capacity ; cd34 ;vf2 ; cells ; peak VO2
treatment ; outpatients ; heart failure ; ejection fraction
case-fatality rate ; concurrent HF ; concurrent HF
CHF ; anthracycline exposure ; stem cell
tension ; muscle strips ; kcl-KI ; treatment ; titin ; titin ; extracellular matrix ; fpassive
reversibility ; heart failure ; myocardial infarction ; m ; Î²-adrenoceptor blockade ; infarcted rats ; metoprolol
aerobic ; resistance training ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ; il6 ; hscrp
readmission ; all-cause readmission ; acr ; potential Preventable Readmission ; pdp ; Centers for Medicare and Medicaid ; 30-day readmission ; cms
congestive heart failure ; ed ; correlation coefficient
exercise ; walking ; Minnesota ; quality of life ; exercise
arginine vasopressin ; aVP ; physiologic ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers ; heart failure ; ejection fraction
physical ; implantable defibrillators ; circulatory support ; transplantation ; heart failure
hypertension diet ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hff
right ventricular pacing ; gene expressions ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
Rats ; hearts ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome ; bcl2 ; Bax ; caspase ; expression
metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor
acute HF ; RELAx-aHF ;ASTRONAUT ; prONTO
hf ; international classification of Diseases ; Ninth revision ; principal discharge diagnosis
pulmonary capillary wedge pressure ; hg ; baseline ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
rad ; q65p ; gating movement ; wild-type rad ; q65p ; rpg proteins
SS20 ; heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
New-onset aortic insufficiency ;AI ; mechanical circulatory ; flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
administration ; pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hh
discharge ; follow-up
heart failure ; refractory ; terminal heart failure
heart failure discharges ; university of Connecticut health Center ; follow-up visits
New York Heart association ;NYha ; Heart Failure ; eplerenone ; standard Heart Failure Medicines ;EMPhaSIS-HF study
echocardiograms ; left ventricular base ; midpapillary ; baseline ; IVc occlusion ; BiVP ; ste ; twist ; basal rotations ; rs
evidence ; drugs ; drugs ; raas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
hf induced ; mice ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
i-mig ; cardiac washout ; carvedilol ; metoprolol ; treatment ; Î²2-adrenergic receptor haplotype
treatment ; acute myocardial infarction ; am ; heart failure ;HF ; complicating ; am
h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ; forkhead box ; o-1 ; cardiac metabolic gene expression ; ATP
bottleneck stent ; implanted ; proximal left anterior descending ; lad ; proximal circumflex artery ; lx ; proximal LCx ; lad ; pigs
postmarketing ; hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; inhibitors ; antihyperglycemic agents
multivariable cox modeling ; Heart Failure Patient Severity index ; hsp ; university of Michigan ; hf ; uab
pde2 overexpression ; cardiomyocytes ; cAMP ; ca2 ; inotropic effect ; basal contractility
ATP ; shock therapy
Cardiac resynchronization therapy ; ct ; dialysis-dependent ; heart failure ; hz ; ct ; dialysis
joint ; cardiorespiratory fitness ;crf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ; hh mortality ; fit ; unfit men
eplerenone ; hyperkalemia ; renal function ; emphaSIS-HF ; eplerenone ; Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ; ghf ; left ventricular ;LV
neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; mechanism of cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ; avd ; interventricular delay ; vd ; ste ; radial strain ;RS
New York Heart association ;NYha ; functional class III ; hh ; ejection fractions ; chronic stable guideline-directed medical therapy ; ght ; united states ; Canada ; europe
non-LBb ; QRs ; hazard ratio ; primary outcome ; QRs
dyssynchronous HF ; myofiber ; velocity ; septum ; myofiber ; stretch rate ; late-activated lateral wall
label-free shotgun proteomics ; proteomics ; transverse aortic constriction ;TAC ; heart failure
transforming growth factor-Î² ; tgf-Î² ; epithelial ; mesenchymal transition markers ; expression of pluripotency markers ; shams
pka ; change ; regulatory ;RIiÎ± ; catalytic ; expression ; rIIÎ± ; ser96) ; phosphorylation ; hz
hf ; left ventricular ejection fraction ; hfpEF ; left ventricular ejection fraction ; RAS- ; Î²-blocker dose changes ; index HF
cross talk ; g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; chronic Î²-adrenergic receptor stimulation ; postischemic heart failure
concentric remodeling ;cr ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ; hpEF ; eccentric hypertrophy ;EH
body ; exercise ; exercise
RV dysfunction ;hazard ratio ; cachexia ;hazard ratio
resting HR ; follow-up ; baseline ; VO2max ; resting HR
tgf-Î² inhibition ; c-Kit ; cell phenotype ; cardiac progenitor function ; cell expansion
NT-probNP ; inflammatory biomarkers ; hscrp ; il6 ; il 6 ; hscrp
BETs ; neurohormonally induced heart disease ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; exercise capacity ; pro-brain natriuretic peptide ; heart failure ; hospitalizations ; ght-treated NYha ; functional class III HF
activation ; p70s6k ; PKc-Î²II ; HDl ; malondialdehyde ; bound ; HDl
mlh ; exercise ; diet ; exercise ; diet
nonpace ; non-DNx ; ham-innervated ; ham-inv
hbc Battery score ; hf ; health ABC ; hf model ; death
ejection fraction ; frail ; biological phenotype ; risk of death ; frailty ; deficit index
hemoglobin ; ghg ; HRQol ; HRQol ; Heart Failure ; exercise training ; hz-action
atrial Fibrillation ; congestive Heart Failure trial ; health care ; expenditures ; QuÃ©bec ; rhythm ; rate-control ; treatment
heart failure ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
report ; calcineurin ;fat signalling ; mir-25 expression ; basic helix-loop-helix ; bhlh ; transcription factor ; dHAND ; hand ; mouse ; myocardium
exercise time ; pss ; btes ; exercise time ; pss ; btes
NT-probNP cutoff point ; admission
prognostic power ; r-r interval oscillations ; non-linear HR ; fractal scaling exponent
diastolic function ; diastolic filling ; relaxation ;viscoelastic ; passive ;stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; ventricular tachycardia ; hv ; vt ; structurally normal hearts ; hNorm
gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; cv
VAD ; ventricular assist device ; ecmo ; extracorporeal membrane oxygenation membrane ; ecmo ; VAD
ischemic events ; ies ; ischemic cardiomyopathy ; icc ; cardiac resynchronization therapy ; defibrillator ; crt-d
heart failure disease management ; evidence-based treatments ; health care system
resistin ; heart failure ; mouse model ; murine resistin ; transgenic ; Retn gene ; hum-retn mice
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; Î²-blockers
tttMena mice ; cardiac injury ; ejection fraction ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; ambulatory Heart Failure trial ; implantable cardioverter defibrillator-ct ; mortality ; heart failure
heart failure ; italy ; confirmatory factor analysis ; cfa ; schfi ; self-care Maintenance ; Self-care management ; Self-care Confidence
mwt ; NYha ; hfpEF ; hff ; therapy ; hfpEF ; death ; hf
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; follow-up ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-erk1/2 scaffold proteins ; cardiac remodelling
CHF ; SD testosterone levels ; exercise ; testosterone
MS ; dynamic ; LV dilatation ; treatment ; heart failure ; hh ; LV ; MS ; hh ; MR ; prolapse ; degenerative mitral valve
New York Heart association ; kccq ; Spearman correlations ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; Î²-blockers ; heart failure ; medical records
c57b ; ang II infusion ; ang II infusion ; uninephrectomy ; ang II infusion ; salt loading ; ang II infusion ; uninephrectomy ; salt loading
early transmitral blood flow velocity ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcp ; systolic heart failure ;HF
systolic indices ;LV ejection fraction ; LV ; strain ;strain rate ; systole ; diastolic indices ; strain rate ; diastole ; early transmitral flow ; sinus rhythm ; follow-up
peak VO2 ; exercise ; body mass ; diet ; body mass
early-onset HF ; late-onset HF
AMI ; hospital ; odds of dying
mass spectrometry ; circulating ; NT-probNP ; physiological proteolysis
ctnt ; NT-probNP ; report ; ctnt ; NT-probNP ; hh prediction model
hfpEF ; New York Heart association ; mean ejection fraction ; fes
left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
baroreflex activity Therapy ; Heart Failure ; ejection Fraction ; carotid baroreflex activation therapy ;BAT ; heart failure ;HF
hazard ratio
hf ; risk factors ; raised blood glucose levels ; obesity ; tobacco ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; la
cRF ; overweight ; obese body mass index
kccq ; hfpEF ;log ; EF
baseline ; egFR ; egFR ; egFR ; hypertension ; diuretics ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ; hz ; pde2-mediated effects ; beta-adrenergic receptor ;Î²-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable ; cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm mitochondrial structure ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; maisel ; Henry
follow-up ; urgent readmission
overexpression ; TTA ; mice ;TAC ; surgery ; cardiac hypertrophy ; post-TAC ; cardiac functional deterioration
echocardiography ; LV ; end-diastolic volume ; ml ; mitral valve opening ; mva ; pressure gradient
p ; diuretic refractory ; hf ; prelated complications
ATP production rates ; post-aac ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart association ; heart failure ;HF ; left ventricular ejection fraction ; permanent periodic breathing ; pb ; report
implantation ; bottleneck stent ; proximal LAD ;LCx ; reversible myocardial ischemia ; open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; AAs
obese ; body mass index ; hff
proangiogenic effects ; VEg pathway ; injected ; adenoviral vector ; veg receptor ; ad-flk ; adenovirus ; ad-c
surgery ; post- lVAD ; AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic ; aortic valve replacement ; CF lVAD ; AI
exercise-induced pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
medline ;EMBAse ; healthstar ; cim ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institute ; evidence based practice
va ; health care systems ; systolic heart failure ; Î²-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; cste ; rvpo ; RS synchrony ; cp ; BiVP
tAPse ; pasp ; tAPse-to-PASp ratio ;TAPSe ; pasp ; cox regression ; kaplan-meier analyses ; tAPse ; pasp
cPET ; CHF ; exercise ; exercise ; exercise
human heart failure ;HF ; mRNA splicing ; voltage-gated cardiac ; na+ channel ; scn5a ; truncated ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; cellular responses ; heart failure ; anthracycline ; malignant disease
economic ; Patient management ; Heart Failure ; cost-effectiveness model ; evidence-based medications ; costs
natriuretic peptides ;NPs ; acute heart failure ; Emergency department ; ed ; acute dyspnea
peak oxygen consumption ; peak VO2 ;ven ; vco2 slope ; exercise ; exercise oscillatory ventilation ; eOV ; end-tidal co2 ;PETco2 ; cardiopulmonary exercise testing
denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; organic lesion ; systolic ; diastolic tethering ; functional etiology ; MR ; MS
tolvaptan ; hyponatremia ; united states ; japon ; congestive heart failure ; diuretic therapy ; serum sodium levels ; systolic function
longitudinal strain ; left ventricle ; echocardiographic measurements ; baseline echocardiography ; ct ; follow-up echocardiograms
platelet-activating factor ;paf ; metabolic enzymes ; heart failure
acute care surgery ; acs ; oHT ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
HFpEF ; ivabradine ; exercise capacity ; left ventricular ; filling pressure response ; exercise ; early diastolic mitral flow velocity ; diastolic mitral annular velocity
renin-angiotensin-aldosterone system ; raas ; hff ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hfpEF
lVET ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ;RAS ; blockers ; Î²-blockers
cardiac performance ; Î²-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; Î²-blockers therapy
SS31 ; congestive heart failure phenotypes ; mitochondrial damage induced ;TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ; ATPase activity ; mRNA levels ; SR ; ca(2+)-pump ; phospholamban ; Î±-myosin heavy chain ; mRNA ; Î²-myosin heavy chain ; metoprolol
HDl ;HDl ; CHF-NYha-III ;HDl ; CHF-NYha-II ;HDl
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
mdc ; mdc ; mdc ; mdc
baseline ; heart failure ; administration of contrast agent ; ms ; administration ; ms
hf ; laa ; dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; exercise training ; hf
report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients with chronic heart failure ; exercise rehabilitation ; chronic heart failure ;CHf ; CardioPulmonary exercise testing ; cPET ; exercise rehabilitation ; china
AA ; ischemic HF pathogenesis ; NYha ; functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
hf-action ; exercise training ; hf ; left ventricular ejection fractions ; HRQol ; Kansas City Cardiomyopathy Questionnaire ; kvq ; baseline
ct ; systolic dysfunction ; resynchronization reverses remodeling ; Systolic left v entricular dysfunction ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egf ; diabetes ; cholesterol ; lDL-cholesterol ; ccnka GG
echocardiography ; LV ; end-diastolic ; LV ; end-diastolic pressure ;wall stress ; lung weight ; acf groups ; sham group
diagnostic performance ; aUC ; aUC
spironolactone ; hospitalization ; adjusted hazard ratio ; death
rate-control ; cardiac procedures ; cardioversions ; costs ; antiarrhythmic drugs ;CAD
diabetes mellitus ; cardiomyopathy ; Î²-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival study ; eheSUS ; post-myocardial infarction ; heart failure ; mortality ; hospitalizations ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-crt ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
heart failure-related mortality ; sudden death
DASh ; srd ; brachial systolic pressure ; central end-systolic pressure ; hg
hf ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
mortality ;HF ; LVEF ; Heart Failure Survey ; israel
left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; negative coronary angiography
european society of Cardiology ; hff ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
activation ; Î²1ARs ; s1PR1s ; myocyte ; cAMP production ; report ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
follow-up ; PAf-cpt ; PAf ; lyso-paf-at ; PAf-AH ; lp-PLA2
heart failure ; ejection fraction ; standard cardiac rehabilitation ; Nordic walking ; exercise
dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle mass ; t-score ; sarcopenic range ; muscle wasting ; t-score ; wasting ; t-score
exercise ; testosterone ; baseline ; peak oxygen uptake ; Beck depression inventory ; leg strength ; medical ; short-Form quality of life ; exercise
RAS- ; Î²-blocker uptitrations ; mortality ; hf ; readmissions ; hf ;hazard ratio
Heart Failure ; exercise training ; hf-action ; social support ; exercise ; social support score ; psss ; barriers to exercise score ; btes
ST2 ; hospitalization ;hazard ratio ; cardiovascular death ; hh ; hospitalization ;hazard ratio ; mortality ;hazard ratio ; hazard ratios ; log2
New York Heart association ; cardiopulmonary exercise testing ; lean mass ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
dopamine ; low-dose nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
ct ; New York Heart association ; heart failure ; left ventricular ejection fraction ; QRs ; echocardiographic evidence ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ;HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP levels ; CAD
baseline ; hf ; activities ; lyso-paf-AT ; PAf-cpt ; PAf ; activities ; PAf-AH ; lp-PLA2
medical ; redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter ; aortic valve procedure ; open surgery ; aortic valve replacement
cutoff value ; plasma ; natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ; ed
cardiac troponin t ; ctnt ; high-sensitivity assay ; natriuretic peptide ;NT-probNP ; biomarkers ; hh ; hh ; Atherosclerosis risk in communities ;ARIc
body mass index ; event rate ;HR ; fat mass ; fat-free mass index
interquartile range ; body mass index ; interquartile range ; COPd ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortality ;HF ; dialysis
eh ; LV contractility ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ; hg
echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; ms ; mva ; pressure gradient ; hg
double-blind ; placebo-controlled clinical trial ; renal optimization strategies evaluation ;ROS ; acute heart failure ; renal dysfunction ; glomerular filtration rate
molecular analysis ; bets ; chromatin-mediated signal transduction ; pol II ; co-activating transcription factor networks ; hh pathogenesis ; nuclear factor ; activated t cells ; naFAT ; nuclear factor-Îºb ;NF-Îºb ; transcription factor
mortality ; exercise tolerance ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
cardiovascular mortality ; hazard ratio ; hazard ratio
ee-cfus ; diabetes ; diabetes ; ee-cfu ; peak VO2 ; diabetes ; EO-cFUs ; peak VO2
immunoblotting ; radioenzymatic- ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; cardiomyocytes ; hh
east ; atrial fibrillation ; stroke prevention trial ; AF ; stroke ; cha2s2VASc score ; rhythm control therapy
exercise capacity ; peak oxygen consumption ;VO2 ; qol ; Minnesota Living with Heart Failure ; mlh ; heart failure-related Qol
TAC-induced proteomic ; mitochondrial-targeted peptide ; SS31 ; mitochondrial function ; upstream signal ; pathway alterations ;TAC ; mitochondrial-targeted peptide ; drugs ; heart failure
left ventricular ejection fraction ; hf ; left ventricular ejection fraction ; hospital ; medical ; financial costs
hf ; hf ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-doppler studies ; natriuretic peptide assessment
eds ; hospitalized ; high-volume EDs
cardiac transplant ; ect ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
hbc Battery ; health ; ABC HF risk model ; discrimination ; c-index ;net-reclassification-improvement ; HF
cfi ; RMsea ; Self-Care Maintenance Scale ; cfi ; RMsea ; self-care management Scale ; cfi ; self-care confidence scale
BAT ; walked ; quality-of-life score ; NYha ; functional class ranking ; change in distribution
hypoalbuminemia ; postoperative ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
heart failure ;HF ; cardiomyopathies ; implantable ; cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; right ventricular assist devices
SAF ; pf ; catheterization ; central venous pressure ; hg ; svr index ; dyn ; cardiac index
admission ; bnp ; EF ; bnp ; borderline
heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio ; death
LV ejection fraction ; velocity ; systolic elastance ; contractile efficiency ; acf ; acf ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
hfpEF ; LV ; normal geometry ; LV hypertrophy ;LVh ; relative wall thickness ;RWt ; cr ; LVh ; rwt
lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; ejection fraction ; heart failure ; ejection fraction
blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio ring 30 ; edwards lifesciences ; irvine
shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; minnesota Living with Heart Failure Questionnaire ; medical
action term ; LVEF ; mortality ; LVEF ; age-by-LVEF
westar-Kyoto ; lean ; zSF1 ; obese ; zSF1 ; obese ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
kaplan-meier curves ; log-rank testing ; UM ; va-RT
af ; af ; hypertension ; sinus rhythm ;hazard ratio
chronic HF-ref ; NYha ; functional class II ; egf ; potassium ; eplerenone ; hyperkalemia ; wRF
body composition ; fm ; FM ; body fat distribution ; dual energy ; x-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;cc ; CHF ; myocardial infarction-both
baseline ; drug dose ; spironolactone ; end point of death ; hh ;hazard ratio ; AAs ;hazard ratio
pulmonary arterial hypertension ; chronic thromboembolic pulmonary hypertension ; right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; hh ; btes ; btes ; cardiovascular death ; hh ; exercise group ;hazard ratio
index ED ; low-volume ED cases ; readmission ; aOR ; high-volume EDs ; aOR
implantable cardioverter-defibrillator deactivation ; implantation ; decisions ; implantable cardioverter-defibrillator deactivation
cardiac magnetic resonance ;hazard ratio ; left atrial area ;hazard ratio ; pulmonary vascular resistance ;hazard ratio ; cardiac events
hf ; systolic ; left ventricular ejection fraction ; hf ; conditions ; New York Heart association ; echocardiographic ; cardiopulmonary exercise test
heart failure ; ABCd ; American college of Cardiology ; acc ;American Heart association ; AHA ; New York Heart association ; nyha ; structural heart disease ; heart failure ; physical ; medical
mva ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow ; mva ; velocity time ; mitral filling flow ; continuous wave doppler echocardiography ; MR ; mitral valve plasty
statitistical significance ; RM ; mortality ; sts ; hh ; cri ; tm ; Cri
hfPSI ; Ann arbor Veterans ; affairs ; hf ; va ; HFPSI ; va-RT ; va ; HFPSI
AAs ; spironolactone dose ; hyperkalemia ; potassium ; hypokalemia ; potassium
LVEF ; long-term mortality ; LVEF ;hazard ratio ; LVEF ; LVEF
hfpEF ;odds ratio ; NYha ; walk test ; mwt ; medications
pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
CAD ; diabetes ; electrocardiographic ; waves ; left bundle branch block ;odds ratio ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco use ;odds ratio
receiver ; operating characteristic curve ; ac ; pcwp ; confidence interval ;septal
trastuzumab-treated patients ; coronary artery disease ; hypertension ; trastuzumab administration ; CHF
LVEF ; clinical composite response ; ct ; ct ; LV ; systolic volume index ; ml ; mass
tgf-Î² signaling ; tgf-Î² receptor ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
hfrf ; diuretics ; co-morbidities ; mwt ; NYha
hf ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mva ; pressure gradient ; hg
systolic heart failure ; ivabradine ; SHIft ; systolic Heart failure ; treatment ; if inhibitor ivabradine trial ; ivabradine ; echocardiographic
Hazard ratios ; pip ;hazard ratio ; pip ; New York Heart association ; functional class
Renal function ; Chronic Kid Disease Epidemiology ; glomerular filtration rate ; egf ; ml ; ml
paradigm-HF ; chronic heart failure ; systolic dysfunction ;LV ; NYha II-III ; bn ; primary endpoint ;cardiovascular death ; hospitalization ; heart failure ; arni ; lz696 ; sacubiltril ; valsartan
LV ; reverse remodeling ; pre-ct ; LV ; end-diastolic ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area ; right atrial area ; right ventricular fractional area change
hyperkalemia ; African Americans ; white ; New York Heart association ;NYha ; hh ; left ventricular dysfunction ; spironolactone ; aldactone evaluation study ;RALes
iRS1 ; irs2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS1 ; irs2 ; heart-specific ; iRS1 ; irs2 ; double-knockout ; h-dko ; mice ; liver-specific ; iRS1 ; irs2 ; double-knockout ; l-dko
b-type natriuretic peptide ; natriuretic peptide ; diagnose ; stable coronary artery disease ; b-type natriuretic peptide ; bnp ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; Î²-blockers ; interquartile range
Therapy ; ivabradine ; change ; diastolic mitral flow velocity ; diastolic mitral annular velocity ; exercise capacity ; ivabradine ; peak oxygen uptake
liberal transfusion protocols ; mortality rates ; i2 ; mortality rates ; acute coronary syndrome
readmission ; early follow-up
hek ;human embryonic kidney ; sphingosine-1-phosphate ; s1p1 ; downregulation ; isoproterenol ; Î²-adrenergic receptor agonist
baseline ; walked distance ;Kansas City ; Cardiomyopathy Questionnaire ; Minnesota ; Heart Failure Questionnaire ; depressive ; beck depression inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; kidney injury
diastolic function ; ea ; ventricular-arterial coupling ; ea
hazard ratios ; disease risk score ; dRS ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
ie ; revascularization ; coronary artery bypass ; surgery ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram
biomedical ; biomedical ; chm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
open-label crossover ; masked outcome assessments ; stable heart failure ; left ventricular ejection fraction ; arg16 ; grln27 ; haplotype ; Î²2-receptor ; carvedilol ; metoprolol
low-volume ED cases ;hospitalization ; ed ; aOR ; aOR ; high-volume ED cases ; aOR ; aOR
health Buddy program ; mortality ;hazard ratio ;HR ; inpatient admissions ; baseline
multivariable-adjusted hazard ratios ; DASh
ctnt ; NT-probNP ;laboratory report ; aRIC ; hh ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hh ; receiver operating characteristic curve ; uc ; discrimination improvement ; net reclassification improvement ; nRI
eplerenone ; hyperkalemia ; renal function ; wRF ; emphaSIS-HF ; heart failure ; ejection fraction ; hf-ref ; New York Heart association ;NYha ; glomerular filtration rate ; egf ; serum potassium
low-dose nesiritide ; urine volume ;nesiritide ; change ; cystatin c level ;nesiritide
Nordic walking ; functional capacity ; mwt ; physical activity ; right grip strength ; depressive ; hospital anxiety and depression Scale
hyperkalemia ; wr ; diabetes ; egf ; systolic blood pressure ; hg ; potassium ; hyperkalemia ; wr ; primary outcome ;hospitalization ; HF ; cardiovascular mortality
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ; dithiothreitol ; dt ; choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; pf-cpt ; catabolic isoenzymes ; pf-acetylhydrolase ; pf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA2 ; leukocytes
ivabradine group ; baseline ; follow-up exercise capacity ; peak oxygen uptake ; exercise-induced ; peak early diastolic mitral flow velocity ; early diastolic mitral annular velocity
CHF ;Odds ratio ; ht ; chest radiation ; hypertension ; genes coding ;NAD ; h-oxidase subunit RAC2 ; hfe ; doxorubicin efflux transporter
baseline ; follow-up ; NYha ; change ; Duke activity status index ; Kansas City Cardiomyopathy Questionnaire ; walk test distance
low-dose dopamine ; urine volume ;dopamine ; change ; cystatin c level ;dopamine
baseline glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart association ; atrial fibrillation ; congestive HF
peak oxygen uptake ; hazard ratio ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
Kansas City ; Cardiomyopathy ; Minnesota ; Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes ; natriuretic peptide ; mitral ; wave ratio
